* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise
in
quarterly revenue when it reports results on July 25.
* The Mason Ohio-based company is expected to report a
15.3% increase in revenue to $97.489 million from $84.53 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. The company's guidance on May 2 2023,
for the period ended June 30, was for revenue between $95.36
million and $97.23 million.
* Refinitiv's mean analyst estimate for AtriCure Inc is for
a
loss of 30 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AtriCure
Inc is
$55, above its last closing price of $54.31.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.34 -0.34 -0.23 Beat 32.1
Dec. 31 2023 -0.17 -0.18 -0.09 Beat 48.8
Sep. 30 2022 -0.25 -0.25 -0.27 Missed -6.8
Jun. 30 2022 -0.29 -0.29 -0.32 Missed -9.3
Mar. -0.31 -0.32 -0.33 Missed -3.2
31 2022
Dec. 31 2021 -0.29 -0.29 -0.30 Missed -3.4
Sep. 30 2021 -0.33 -0.32 2.11 Beat 750
Jun. 30 2021 -0.34 -0.33 -0.36 Missed -7.5
This summary was machine generated July 21 at 21:56 GMT. All
figures in US dollars unless otherwise stated